Gild Volume was so high due to such a large price drop and the high volume of investors shorting the stock over the past several weeks and especially in the last several days. Abbv has not had as much price drop nor the volume impact. Today, both stocks are being factored by shorts covering. Due to the holidays and normal light volume trading it will be well into January before everything shakes out and even then we will be into earnings release. Merry Christmas.
Own both stocks and buying Gild on the downswing. My biggest problem with Gild is that they paid $13 Billion for HVC and that is a huge up front investment allowing for a lot of pricing opportunities for other HVC companies with a lot smaller up front investment to grab market share and still allowing for very good margins. Over time I hope Gild will recoup its $13 Billion but do not know how much more they will make on this drug. This investment forced them to price themselves out of the market. Hopefully their next generation drug will make up for this investment.
It would be in your best interest to study the clinical data and also understand the FDA approved labeling before making statements and running your credibility.
If the big investors are all up in arms over this why was trading volume down from average shares yesterday and volume the day before was at normal volume?
You may want to review the clinical data from both companies. Nothing in data that I have seen saying one drug is superior over the other whether you are looking at 8 weeks, 12 weeks or 24 weeks. As a matter of fact the harder case treatments point to better results and more clinical data for the Abbv product. Inconvenience is the biggest issue (4 pills vs. 1 pill). If this was a lifetime taking treat this would be a very big factor but for a limited time treatment not nearly as big of a factor. Not only that, in a relative short span of time a new generation of products for HVC will be hitting the market.
I would suspect this deal has been in the making for some time and both Express and Abbv lawyers reviewed this proposal forwards and backwards. Abbv can charge whatever price and discounts they so desire as long as they did not collude with their competitors. Express Scripts may be the ones that will have some explaining to do for not offering Gild products and the individual having to pay the price difference. At this point in time we do not even know what the agreement on price is. Just the difference between $83m and $93M for 12 weeks is a big enough difference for the Express decision.
Thought you sold all your Abbv shares?? If so, go whine on the GILD board. You will be in good company, There are a lot of whiners over there.
Government pricing is based on the lowest discount price. So why would the government not like this deal? Simply means that Medicare and Medicaid choice will be for the Abbvie product including all other Federal Government purchases.
Abbvie stock is up 27% YTD and the approval of HVC has been priced into the stock over the past several months. I do not know what the discount is to Express Scripts but keep in mind Abbvie did not buy their product for $13 Billion as did Gld. which leaves a lot of room to reduce price and still walk away with plenty of margin and market share. Greed and over paying for a product opens the doors for competition.
What is your point? The price of Abbv during the time that the merger looked like a go the price of Abbv was in the $55 range. Today it is at $65 after the so called failed merger. YTD Abbv is up 24% and the market is up 8%. If that is a negative affect on the stock, I will take it any day of the week.
Is this your wishful thinking or do you have some hard facts in your reference to the FDA?
Chocolots, does not sound like you have enough brains to be a smart short player. The smart players keep their mouths shut and play the game.
Amazing. Same thing was said on the Abbvie message board about Abbvie stock.
5 cents a quarter would be a 22% increase. I hope you are correct but I think this would be on the high side. Maybe 5 to 10 cents for the year which would be a 6 to 11% increase.
You need to do your homework. All this information except pricing and FDA approval are in the clinical reports. Why would they show their hand on pricing before market introduction? The FDA never gives exact dates for approval. Everyone six months ago knew FDA approval would most likely be in December. That is why there are no sales in the 2014 ABBV outlook. Of course ABBV investors would liked to have been first to market but that did not happen. Is this your first time through an NDA? If all this is worrisome for you, you should not invest in Pharmaceutical Companies.